Insulin-Like Growth Factor 1 (IGF-1) in Parkinson's Disease: Potential as Trait-, Progression- and Prediction Marker and Confounding Factors.
Insulin-Like Growth Factor 1 (IGF-1) in Parkinson's Disease: Potential as Trait-, Progression- and Prediction Marker and Confounding Factors.
复制标题
帕金森氏病中的胰岛素样生长因子1（IGF-1）：作为性状，进展和预测标记和混杂因素的潜力。
DOI：
10.1371/journal.pone.0150552
复制
发表时间：
2016
期刊：
影响因子：
3.7
通讯作者：
Berg D
中科院分区：
文献类型：
--
作者：
Bernhard FP;Heinzel S;Binder G;Weber K;Apel A;Roeben B;Deuschle C;Maechtel M;Heger T;Nussbaum S;Gasser T;Maetzler W;Berg D
指示帕金森病（PD）的特征、进展和预测病理和症状的生物标志物往往缺乏特异性或可靠性。研究个体之间和一段时间内的生物标志物差异以及混杂因素的影响对于评估PD中的生物标志物（例如胰岛素样生长因子1（IGF-1））至关重要。在纵向MODEP研究中，对37例PD患者和22例健康对照（HC）的IGF-1血清水平进行了长达8次半年一次的访视。比较PD患者和HC患者的IGF-1基线水平和IGF-1的年度变化，同时考虑基线疾病持续时间（19例早期：≤3.5年; 18例中度：>4年）、年龄、性别、体重指数（BMI）和常见的调节IGF-1的医学因素。此外，研究了基线IGF-1与运动、认知和抑郁症状的年度变化以及药物剂量的相关性。中度PD患者（130±26 ng/mL; p = 0.004），而非早期PD患者（115±19，p> 0.1），与HC患者（106±24 ng/mL; p = 0.017）相比，基线IGF-1水平显著升高。HC患者年龄与IGF-1水平呈显著负相关（r =-0.47，p = 0.028），PD患者年龄与IGF-1水平无相关性（r =-0.06，p> 0.1）。BMI在整个组中呈负相关（r = -.28，p = .034）。IGF-1的年度变化在各组之间没有显著差异，并且与疾病持续时间无关。基线IGF-1水平与临床参数的年度变化无关。血清中IGF-1升高可能区分中度PD和HC患者。然而，血清IGF-1作为PD的特征、进展和预测标志物的价值是有限的，因为IGF-1显示出较大的个体间和个体内变异性，并且可能受到几种混杂因素的调节。
Biomarkers indicating trait, progression and prediction of pathology and symptoms in Parkinson's disease (PD) often lack specificity or reliability. Investigating biomarker variance between individuals and over time and the effect of confounding factors is essential for the evaluation of biomarkers in PD, such as insulin-like growth factor 1 (IGF-1). IGF-1 serum levels were investigated in up to 8 biannual visits in 37 PD patients and 22 healthy controls (HC) in the longitudinal MODEP study. IGF-1 baseline levels and annual changes in IGF-1 were compared between PD patients and HC while accounting for baseline disease duration (19 early stage: ≤3.5 years; 18 moderate stage: >4 years), age, sex, body mass index (BMI) and common medical factors putatively modulating IGF-1. In addition, associations of baseline IGF-1 with annual changes of motor, cognitive and depressive symptoms and medication dose were investigated. PD patients in moderate (130±26 ng/mL; p = .004), but not early stages (115±19, p>.1), showed significantly increased baseline IGF-1 levels compared with HC (106±24 ng/mL; p = .017). Age had a significant negative correlation with IGF-1 levels in HC (r = -.47, p = .028) and no correlation in PD patients (r = -.06, p>.1). BMI was negatively correlated in the overall group (r = -.28, p = .034). The annual changes in IGF-1 did not differ significantly between groups and were not correlated with disease duration. Baseline IGF-1 levels were not associated with annual changes of clinical parameters. Elevated IGF-1 in serum might differentiate between patients in moderate PD stages and HC. However, the value of serum IGF-1 as a trait-, progression- and prediction marker in PD is limited as IGF-1 showed large inter- and intraindividual variability and may be modulated by several confounders.